These findings identify SIRT1 as a negative regulator of VSV therapy and suggest that SIRT1 inhibition could be an effective strategy to increase VSV efficacy, particularly in prostate tumors with strong intrinsic antiviral defenses. Here, SIRT1 is linked to prostate neoplasm.